Brief Report
Volume 6:12, 2022

Clinical and Medical Case Reports

ISSN: 2684-4915

Open Access

A Little Remark on New Parkinson's disease Treatment Methods

Emily Wilson*

Department of Pharmaceutical Sciences, University of Skovde, Skovde, Sweden

Introduction

Parkinson's disease (PD) is a chronic, mildly neurodegenerative disease of the focused sensory system that affects both the inception and completion of intentional actions as well as mental impairment. It is thought to be the second most well-known neurodegenerative disease after Alzheimer's disease. The primary morphological change common to all kinds of PD is the lack of dopamine brought on by neuronal degeneration and the absence of nerve cells in the substantia nigra standards compacta that contain melanin (SNpc). For people over 60, the fundamental adverse effects—tremors, problems with balance and posture, a slowing down of movement or bradykinesia, and the stability of peripherals—become more obvious. A fountain of occasions is where side effects start.

Description

When SNpc neurons are lost, the dopaminergic pathway starts to deteriorate. As a result, the amount of dopamine that the mind habitually produces significantly decreases. The most problematic concept in neurodegenerative diseases is the vulnerability of the course of degeneration's onset. The discovery of protein totals in the cerebral cortex made the study of proteins relevant to neurological conditions like Parkinson's disease. Then, at that time, this collection causes a necessity for responses on how it started and what might genuinely cause such occurrences.

The truth is that the unusual protein combination, proteotoxic stress, or faults in the protein combination, and the oxidative strain that proteins experience when they are unstable are the origins of all neurodegenerative diseases, which are always changing. When a drug is deemed temperamental, it typically transfers its precariousness to nearby pathways that are included. This is what makes neurodegenerative diseases so intriguing because they typically started with simple protein tumult, gradually leading to a damaged pathway and hence the term "degeneration". A study by Michel that demonstrated how the misfolding and accumulation of ASN in the neurotransmitter led to the degeneration and potential ever-evolving corruption of the SNpc dopamine neurons is a good example [1,2].

Nanotechnology is a sophisticated branch of science that deals with objects and materials with a nanoscale (nm) scale. It is unique in the field of drug research due to the versatility of its uses. The concept of nanoparticles is the one aspect of nanotechnology that is most relevant to this investigation. Blood can flow via veins in the human body and be carried there. The BBB, as its name implies, serves as a barrier for any material that needs to cross blood-brain barriers to reach the brain. It is composed of a single layer of entrapped endothelial cells (ECs) and wall-painting cells known as persistent and non-fenestrated, which are in charge of regulating the homeostasis of the focused sensory system (CNS). Sadly, the blockage that protects the mind from harmful chemicals prevents the majority of pharmacologically recommended treatments for CNS issues from working as intended. These drugs are often macromolecules that are either unable to cross the BBB or ready to do so but not in sufficient quantities to be pharmacologically significant. As dopamine isn't at its usual level, the mind's typical response to disorders like Parkinson's disease (PD) is that it tries to activate the dopamine receptors to provide dopamine as usual.

The argument against PD is that the SNpc already has a problem because it started deteriorating or corrupting, which is why even though the mind trains it to produce a usual amount of dopamine, it can no longer supply the same amount because something is wrong with its capacity. This is where anti-drugs Parkinson's specifically include levodopa and frequently combine it with other dynamic ingredients to apply the effect. Levodopa, often known as L-dopa, is the lipophilic precursor to the BBB-tricky dopamine, which continues to be the best quality level of treatment for Parkinson's disease symptoms. Practically speaking, levodopa is administered coupled with carbidopa, a peripheral dopa decarboxylase inhibitor that prevents the premature conversion of levodopa to dopamine because the latter cannot pass the blood-brain barrier. The amount of L-dopa being delivered to the brain increases significantly when carbidopa and levodopa are combined, but it's important to note that carbidopa isn't responsible for the increase in dopamine because it primarily acts as a support for levodopa and has no synergistic effects [3-5].

Conclusion

Even however, not all of the highlighted articles in this study utilised dendrimers as the counter's nano-transporters. The researcher sees it as a potential opportunity to look into how Parkinson's drugs behave in a nano environment. These writings are specifically mentioned because a dendrimer may be created from them. The depiction tests and discoveries are now finalised because there are currently just a few studies focusing on the interactions of other nanomaterials with those with other nanomaterials. Future studies on dendrimer production will then have a more solid foundation thanks to this at that moment.Since the important synapse is crucial for PD, the publications about dopamine organisation using an alternative methodology in the BBB are really two creative approaches. This collection of data is intended to demonstrate how useful and creative the application of PD medicines to nanomaterials is, particularly given the significant role that dendrimers play in preventing the overall growth of totals. In the end, the expert sees it as a way that the dendrimers can definitely meet a need in terms of tending to the collection's underlying cause rather than tending to it after the degeneration started. We may assume that different ages of dendrimers have a typical point in the evolution of shaky beta designs of ASN based on the information we have gathered about the dendrimers.

Acknowledgement

None.

Conflict of Interest

The authors declare that there is no conflict of interest associated with this manuscript.

***Address for Correspondence:** Emily Wilson, Department of Pharmaceutical Sciences, University of Skovde, Skovde, Sweden, E-mail: emily1978w@gmail.com*

Received: 03 November, 2022, Manuscript No. cmcr-23-90857; **Editor assigned:** 04 November, 2022, Pre QC No. P-90857; **Reviewed:** 11 November, 2022, QC No. Q-90857; **Revised:** 21 November, 2022, Manuscript No. R-90857; **Published:** 08 December, 2022, DOI: 10.37421/2684-4915.2022.6.239

References

1. Moreau, Caroline, Anne Sophie Rolland, Elsa Pioli and Qin Li. "Intraventricular dopamine infusion alleviates motor symptoms in a primate model of Parkinson's disease." *Neurobiol Dis* 139 (2020): 104846.
2. Przedborski, Serge, Miquel Vila and Vernice Jackson-Lewis. "Series Introduction: Neurodegeneration: What is it and where are we?." *J Clin Investig* 111 (2003): 3-10.
3. Naqvi, Saba, Archna Panghal and S. J. S. Flora. "Nanotechnology: a promising approach for delivery of neuroprotective drugs." *Front Neurosci* 14 (2020): 494.
4. Lochhead, Jeffrey J., Junzhi Yang, Patrick T. Ronaldson and Thomas P. Davis. "Structure, function, and regulation of the blood-brain barrier tight junction in central nervous system disorders." *Front Physiol* 11 (2020): 914.
5. Georgieva, Julia V., Dick Hoekstra and Inge S. Zuhorn. "Smuggling drugs into the brain: An overview of ligands targeting transcytosis for drug delivery across the blood–brain barrier." *Pharmaceutics* 6 (2014): 557-583.

How to cite this article: Wilson, Emily. “A Little Remark on New Parkinson's disease Treatment Methods.” Clin Med Case Rep 6 (2022): 239.